Form 4: Singular Genomics Systems CEO Andrew Spaventa Reports Share Disposal Following Merger
SEC Form 4
Andrew Spaventa, CEO of Singular Genomics Systems, reports the disposal of common stock and derivative securities due to the merger with Singular Genomics Parent, LLC, where shares were converted to $20.00 per share in cash.
Summary
- Andrew Spaventa, the CEO of Singular Genomics Systems, filed a Form 4 detailing changes in beneficial ownership.
- The filing is related to the merger between Singular Genomics Systems and Singular Genomics Parent, LLC.
- As a result of the merger, Spaventa's shares of common stock were converted into the right to receive $20.00 per share in cash.
- Spaventa also disposed of stock options and restricted stock units (RSUs), which were either cancelled for cash or no consideration, depending on the exercise price.
- Some shares were contributed to Parent via a Contribution and Exchange Agreement with The Andrew K. Spaventa Living Trust.
- The filing indicates both direct and indirect ownership of securities.
- The effective date of the transactions is February 21, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document primarily reports transactions related to a previously announced merger.
Future Outlook
The merger between Singular Genomics Systems and Singular Genomics Parent, LLC has been completed, resulting in the conversion of shares to cash.
Industry Context
This announcement reflects a merger and acquisition event in the genomics sector, where companies are often acquired to consolidate technologies or expand market reach.
Related Party Transactions
- The Andrew K. Spaventa Living Trust and Axon Holdings, LLC are related parties involved in the transactions.
Stakeholder Impact
- Shareholders received $20.00 per share in cash as a result of the merger.
- Employees with stock options and RSUs received cash payments based on the merger terms.
Key Dates
| Date | Description |
|---|---|
| April 9, 2014 | Date of The Andrew K. Spaventa Living Trust |
| December 22, 2024 | Date of the Agreement and Plan of Merger |
| February 21, 2025 | Date of Earliest Transaction, Contribution and Exchange Agreement, and filing date of the Form 4 |
| December 16, 2029 | Expiration date of some stock options |
| March 04, 2032 | Expiration date of some stock options |
| March 15, 2033 | Expiration date of some stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.